Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LSA4 + cyclophosphamide + methotrexate + daunomycin + L-asparaginase + BCNU
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral, Intramuscular, Intrathecal, Subcutaneous
01
Overview
This is a multi-agent chemotherapy regimen composed of six drugs: LSA4, cyclophosphamide, methotrexate, daunomycin (also known as daunorubicin), L-asparaginase, and BCNU (carmustine). Such combinations are typically used in the treatment of hematologic malignancies like acute lymphoblastic leukemia (ALL) and certain lymphomas. Each component has a distinct mechanism of action: - Cyclophosphamide is an alkylating agent that crosslinks DNA to prevent cell division[1][2][3]. - Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, blocking DNA synthesis. - Daunomycin/daunorubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II. - L-asparaginase depletes asparagine from plasma, starving leukemic cells unable to synthesize this amino acid[6][8][10]. - BCNU (carmustine) is a nitrosourea alkylating agent causing DNA crosslinking. The combination targets rapidly dividing cancer cells through multiple cytotoxic mechanisms.
- Other names
- LSA4 + cyclophosphamide + methotrexate + daunomycin + L-asparaginase + BCNULSA4 regimenLSA-4 regimenLSA 4 regimen
02
Targets
TOP2A (DNA topoisomerase II)DNADHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on LSA4 + cyclophosphamide + methotrexate + daunomycin + L-asparaginase + BCNU.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LSA4 + cyclophosphamide + methotrexate + daunomycin + L-asparaginase + BCNU.